Side by side
Eloralintide vs Orforglipron
Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| Eloralintide | Orforglipron | |
|---|---|---|
| What it is | An amylin receptor agonist that produced up to 20% weight loss in phase 2, as a single agent. That last part is what makes it notable. | The first GLP-1 pill that is a true small molecule. Approved in April 2026, and taken any time of day with no food or water restrictions. |
| EvidenceHow much human evidence exists, not how well it works. | Clinical trials | Approved |
| Regulatory statusReviewed 2026-08-18 | Not approved anywhere. Phase 2 is complete and phase 3 began in late 2025. Anything sold as eloralintide is a research chemical produced outside the controls a future approval would rest on. | Approved by the FDA on 1 April 2026 as Foundayo, for chronic weight management in adults with obesity, or overweight with a weight-related condition. The first non-peptide, small-molecule GLP-1 receptor agonist approved for weight loss. |
| Routes | Subcutaneous | Oral |
| Half-life | 170 hours | 30 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $8.90/mg | $40.00/mg |
| Median per mg | $18.25/mg | $40.00/mg |
| Vendors with a price | 6 | 1 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze once mixed. | Not applicable. This is a tablet. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.